Michael Lyons, OD
Optometrist · West Chester, OHNPI 1336177419
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Haag-streit USA, Inc. accounts for 88.7% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $11,976 and has fallen 94.6% since, to $646 in 2025. Among optometrist clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $156.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Haag-streit USA, Inc.$13K
- Johnson & Johnson Vision Care, Inc.$257
- Bausch & Lomb Americas Inc.$248
- Alcon$182
- Oyster Point Pharma, Inc.$131
- Coopervision Inc.$123
- plus $714 from 19 others
What the payments were for
- Consulting fees$7,00048%
- Speaking & faculty fees$4,50031%
- Food & beverage$2,82319%
- Gifts$2602%
- Entertainment$1021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Haag-streit USA, Inc. | 23 | $13,029 |
| Johnson & Johnson Vision Care, Inc. | 13 | $257 |
| Bausch & Lomb Americas Inc. | 8 | $248 |
| Alcon | 9 | $182 |
| Oyster Point Pharma, Inc. | 7 | $131 |
| Coopervision Inc. | 2 | $123 |
| Tarsus Pharmaceuticals, Inc. | 4 | $117 |
| Biotissue Holdings Inc. | 5 | $103 |
| Optos, Inc. | 2 | $102 |
| Harrow Eye, LLC | 2 | $55 |
| Lombart Brothers, Inc. | 2 | $53 |
| AbbVie | 2 | $40 |
| Sight Sciences, Inc. | 2 | $32 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $31 |
| Kala Pharmaceuticals, Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Spark Therapeutics, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
| Maculogix, Inc. | 1 | $11 |
| LKC Technologies, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$118
- MiSight Contact Lens$109
How this compares
$14,685 in reported general payments places this provider in the 95th percentile of 1,995 optometrist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 25 | $26,990 |
| Timolol Maleate | 66 | $2,387 |
| Fluorometholone | 40 | $2,219 |
| Loteprednol Etabonate | 18 | $1,618 |
| ValacyclovirValacyclovir Hcl | 31 | $1,360 |
| Prednisolone Acetate | 28 | $745 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $455 |
| Latanoprost | 56 | $373 |
| Doxycycline Hyclate | 17 | $242 |
| Brimonidine Tartrate | 30 | $157 |
| Acyclovir | 19 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $40 | $26,99025 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $31 | $1,61818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,995 optometrist providers in Ohio.
Other optometrist in West Chester
- Mile BrujicBowling Green$1.3M
- Gregory DenaeyerColumbus$846K
- Cory LappinMontgomery$367K
- Chris SmileyColumbus$305K
- Thomas ChesterCleveland$300K
- Carly RoseCincinnati$203K
- Wendy HallierReynoldsburg$200K
- John LahrCincinnati$145K
- Erin RueffColumbus$131K
- Mary YackeyCincinnati$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.